Plus Therapeutics, Inc.
PSTV · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | -$0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 18.5% | 2,093.3% | – | – |
| Gross Profit | $0 | -$0 | -$0 | -$0 |
| % Margin | 85.4% | -97.2% | -217.9% | – |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -144.3% | -258.4% | -8,416.1% | – |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -222.8% | -271% | -9,051.3% | – |
| EPS Diluted | -2.34 | -4.24 | -11.55 | -17.78 |
| % Growth | 44.8% | 63.3% | 35% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |